New Humira decision changes venue selection playbook for US biosimilar patent disputes
A recent court ruling suggests that plaintiffs will enjoy more latitude on venue selection when suing biologics imitators
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.